Latest News & Features
Americas
Past successes by trailblazers in other biotechnological fields could assist potential patentees navigate legal bumps along the road to IP protection for CRISPR-related inventions, as Patricia Carson and Ashley Ross of Kirkland & Ellis describe. 9 November 2017
Americas
Fake pharmaceuticals not only harm innovators, they can have tragic consequences, and require a robust response from the authorities. LSIPR assesses how officials, particularly in South America, are responding to the threat. 1 November 2017
Asia
Based in Singapore, biotech company Aslan Pharmaceuticals specialises in developing new treatments to fight cancers that are prevalent in Asia, often requiring licensing deals to ensure it is fully equipped. LSIPR spoke to general counsel Ben Goodger to find out more. 1 November 2017
Americas
With the PTAB facing questions over its authority and even constitutionality, life sciences companies seem to be faring well, at least compared to other industries, as LSIPR finds out. 1 November 2017
Americas
Following the signing of a historic trade agreement with the EU, Canada now has a system of patent term extension. LSIPR considers the impact for pharmaceutical patentees. 1 November 2017
Americas
CRISPR offers ground-breaking opportunities for tackling diseases and genome defects, but its use must be carefully managed to avoid the obvious ethical problems that will arise, as Sanchith Shivakumar of Anand and Anand reports. 26 October 2017
Americas
Owners of biotech inventions may find Mexico an attractive country in which to apply for patent protection because of its non-restrictive patent law and its practical approach to examination, as Eder Gutiérrez of Clarke Modet & Co outlines. 26 October 2017
Americas
Those working in the field of genetic sequence must clearly understand the subtleties of sequence searching, in order to avoid the risks of infringement and invalidity, as Ellen Sherin of GQ Life Sciences finds out. 26 October 2017
Big Pharma
Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe. 26 October 2017
Americas
Samantha Salim and Kene Gallois of Daniel Legal & IP Strategy investigate how Brazil’s patent office and health regulatory agency are coping with the complicated examination of pharmaceutical patent applications. 24 October 2017